Conor P Cahill (Conor Cahill)

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 3

Top Topics

Randomized Controlled Trial

Placebo Controlled

Top Venues

Human vaccines & immunotherapeutics

Annals of internal medicine

Janssen Vaccines and Prevention BV

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Janssen Vaccines and Prevention BV May 01 2017

Netherlands

Compound Development Team Leader, Polio & Zika vaccines :: Viral Vaccines

Publications

Anna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, Delia Caparas-Yu, Astrid Greijer, Michel Duchene, Gert Scheper, Vitalija van Paassen, Mathieu Le Gars, Conor P Cahill, Hanneke Schuitemaker, Macaya Douoguih, Jeanne-Marie Jacquet
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age. Human vaccines & immunotherapeutics 18 (5) (2022)
Nadine C Salisch, Kathryn E Stephenson, Kristi Williams, Freek Cox, Leslie van der Fits, Dirk Heerwegh, Carla Truyers, Marrit N Habets, Diane G Kanjilal, Rafael A Larocca, Peter Abbink, Jinyan Liu, Lauren Peter, Carlos Fierro, Rafael A De La Barrera, Kayvon Modjarrad, Roland C Zahn, Jenny Hendriks, Conor P Cahill, Maarten Leyssen, Macaya Douoguih, Johan van Hoof, Hanneke Schuitemaker, Dan H Barouch
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. Annals of internal medicine 174 (5) (2021)
Isabel Leroux-Roels, Geert Leroux-Roels, Georgi Shukarev, Hanneke Schuitemaker, Conor P Cahill, Richard de Rooij, Martin Struijs, Hester van Zeeburg, Jeanne-Marie Jacquet
Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults. Human vaccines & immunotherapeutics 17 (5) (2020)